Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173667
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Escobar, Carlos | - |
dc.contributor.author | Varela, Luis | - |
dc.contributor.author | Palacios, Beatriz | - |
dc.contributor.author | Capel, Margarita | - |
dc.contributor.author | Sicras, Antoni | - |
dc.contributor.author | Sicras, Aram | - |
dc.contributor.author | Hormigo, Antonio | - |
dc.contributor.author | Alcázar, Roberto | - |
dc.contributor.author | Manito Lorite, Nicolás | - |
dc.contributor.author | Botana, Manuel | - |
dc.date.accessioned | 2021-02-09T08:09:01Z | - |
dc.date.available | 2021-02-09T08:09:01Z | - |
dc.date.issued | 2020-10-20 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173667 | - |
dc.description.abstract | Background: Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods: Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019. Results: We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs. Conclusions: During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12913-020-05828-9 | - |
dc.relation.ispartof | BMC Health Services Research, 2020, vol. 20 | - |
dc.relation.uri | https://doi.org/10.1186/s12913-020-05828-9 | - |
dc.rights | cc by (c) Escobar et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Insuficiència cardíaca | - |
dc.subject.classification | Antidiabètics | - |
dc.subject.other | Hypoglucemic agents | - |
dc.subject.other | Heart failure | - |
dc.title | Costs and healthcare utilisation of patients with heart failure in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-08T10:27:50Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33081776 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
EscobarC.pdf | 958.96 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License